Braun Iv Catheters
B. Braun Medical Inc. (B. Braun) announces its latest contract with Premier Purchasing Partners, the group purchasing unit of Premier, Inc., which will provide Premier’s members – a network of approximately 2,400 U.S. hospitals and 70,000 other healthcare facilities – with the continued benefit of B. Braun’s comprehensive portfolio of IV therapy products and solutions at specially terms.
The three-year agreement went into effect on Oct. 1, 2010 and stands to reinforce the strength of the relationship B. Braun has built with Premier over the years. This is B. Braun’s third contract renewal, amounting to a total of 6 years of partnership.
"We look forward to continuing our partnership with Premier in an effort to improve patient care and safety within the medical device industry," says Tom Sutton, vice president of vascular access and IV systems for B. Braun Medical Inc. "We attribute this win to the strength of our proven, truly passive safety technology."
...The cost study, conducted by a team of researchers from Moores Cancer Center at the University of California San Diego Medical Center, reviewed all five commercially available CSTD systems: the ChemoClave(TM) by ICU Medical, Inc.; EquaShield® by EquaShield Medical, Ltd.; OnGuard(TM) by B. Braun Medical, Inc.; PhaSeal® by Carmel Pharma, Inc.; and Texium®/SmartSite® by CareFusion Corp. To determine price, researchers included the actual number of components needed for a closed-system secondary infusion based on compounding techniques and intravenous administration set configuration in compliance with their institutional policies and practice guidelines. The cost of each individual component necessary to compound and administer a hazardous drug via a secondary infusion set for each CSTD was based on advertised prices at the time of the study, and individual component costs added together to generate a total cost for a single infusion. For indirect costs, researchers weighed the amount of waste generated by each system. Cost and waste totals for individual infusions were then multiplied by 15,312 infusions (average of 1,276 monthly infusions) to generate an annual acquisition cost and waste per system.
|
Last year, B Braun had recently initiated a series of cases against Indian medical device maker Poly Medicure in the area of safety IV catheters. |
|
Key players profiled in the report include Angiotech Pharmaceuticals, Argon Medical Devices, Bard Biopsy Systems, Becton, Dickinson and Company, B. Braun |
